Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Isaac Yaniv, Genevieve Laureys, Penelope Brock, Jean Marie Michon, Cormac Owens, Toby Trahair, Godfrey Chi Fung Chan, Ellen Ruud, Henrik Schroeder, Maja Beck Popovic, Guenter Schreier, Hans Loibner, Peter Ambros, Keith Holmes, Maria Rita CastellaniMark N Gaze, Alberto Garaventa, Andrew D J Pearson, Holger N Lode

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences